
Startup Nilo Launches With $101M for Autoimmune Drugs That Target ‘Brain-Body Circuits’
Nilo Therapeutics’ Series A round was led by The Column Group, DCVC Bio, and Lux Capital. The preclinical startup is developing drugs targeting neural circuits that control systemic inflammation.